Axsome Therapeutics
NY - New York
BiotechnologyFocus: CNS treatments
Axsome Therapeutics is a life sciences company focused on CNS treatments.
Neurology
Open Jobs
182
Products & Portfolio (3)
AUVELITY
dextromethorphan hydrobromide, bupropion hydrochloride
Peak
ORAL · TABLET, EXTENDED RELEASE
(an ionotropic glutamate receptor) and a sigma-1 receptor agonist. The mechanism of dextromethorphan in the treatment of MDD is unclear. The mechanism of action of bupropion in the treatment of MDD is unclear; however, it may be related to noradrenergic and/or dopaminergic mechanisms. Bupropion increases plasma levels of dextromethorphan by competitively inhibiting cytochrome P450 2D6, which catalyzes a major biotransformation pathway for dextromethorphan. Bupropion is a relatively weak inhibitor of the neuronal reuptake of norepinephrine and dopamine and does not inhibit monoamine oxidase or the reuptake of serotonin.
major depressive disorder (MDD) in adults
2022
0
SUNOSI
solriamfetol
Peak
ORAL · TABLET
Dopamine Uptake Inhibitors
2019
0
SYMBRAVO
meloxicam, rizatriptan
Growth
ORAL · TABLET
Cyclooxygenase Inhibitors
2025
0
Pipeline & Clinical Trials
Sunosi
NarcolepsyClinical Trials (1)
NCT06413420SUNOSI® (Solriamfetol) Pregnancy Registry
N/ASolriamfetol 150 mg Oral Tablet
NarcolepsyClinical Trials (1)
NCT05008341Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Oral Administration
Phase 1AXS-05
Smoking CessationClinical Trials (1)
NCT03471767AXS-05 Phase II Trial on Smoking Behavior
Phase 2AXS-12
NarcolepsyClinical Trials (1)
NCT03881852Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)
Phase 2Solriamfetol
Multiple SclerosisClinical Trials (1)
NCT06170970Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
Phase 2Phase 2
Clinical Trials (1)
NCT03595579Assessing Symptomatic Clinical Episodes in Depression
Phase 2Phase 2
Clinical Trials (1)
NCT04608396Mechanistic Evaluation of Response in TRD (MERIT)
Phase 2Phase 2
Clinical Trials (1)
NCT04634669Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)
Phase 2Phase 2
Clinical Trials (1)
NCT04971291An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients
Phase 2Phase 2/3
Clinical Trials (1)
NCT03226522Addressing Dementia Via Agitation-Centered Evaluation
Phase 2/3AXS-12
NarcolepsyClinical Trials (1)
NCT05059223A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy
Phase 3AXS-14
FibromyalgiaClinical Trials (1)
NCT07398417Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design
Phase 3Solriamfetol 300 mg
Major Depressive DisorderClinical Trials (1)
NCT06360419Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol
Phase 3AXS-07
MigraineClinical Trials (1)
NCT03896009Maximizing Outcomes in Treating Acute Migraine
Phase 3Solriamfetol 150 mg
ADHDClinical Trials (1)
NCT05972044A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)
Phase 3Clinical Trials (1)
NCT06736509An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study
Phase 3Phase 3
Clinical Trials (1)
NCT02741791A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder
Phase 3Phase 3
Clinical Trials (1)
NCT02504008CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1
Phase 3Solriamfetol 150 mg
Binge-Eating DisorderClinical Trials (1)
NCT06413433Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
Phase 3Clinical Trials (1)
NCT04947553A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation
Phase 3Clinical Trials (1)
NCT04797715Assessing Clinical Outcomes in Alzheimer's Disease Agitation
Phase 3AXS-07
MigraineClinical Trials (1)
NCT04068051Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT)
Phase 3Solriamfetol 150 mg
Excessive SleepinessClinical Trials (1)
NCT06568367Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)
Phase 3AXS-07
MigraineClinical Trials (1)
NCT05550207Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)
Phase 3Solriamfetol 75mg, 150 mg, or 300 mg
Binge-Eating DisorderClinical Trials (1)
NCT06878976Open-Label Safety Study of Solriamfetol in Subjects With Binge Eating Disorder
Phase 3AXS-12
NarcolepsyClinical Trials (1)
NCT05113745A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)
Phase 3AXS-02
Osteoarthritis, KneeClinical Trials (1)
NCT02746068A Study to Assess the Efficacy and Safety of AXS-02 in Subjects With Knee OA Associated With Bone Marrow Lesions
Phase 3AXS-05
DepressionClinical Trials (1)
NCT04019704A Trial of AXS-05 in Patients With Major Depressive Disorder
Phase 3Clinical Trials (1)
NCT05557409A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
Phase 3Phase 3
Clinical Trials (1)
NCT04039022Open-Label Safety Study of AXS-05 in Subjects With Depression
Phase 3AXS-07
MigraineClinical Trials (1)
NCT04163185Initiating Early Control of Migraine Pain and Associated Symptoms
Phase 3Solriamfetol Oral Tablet
Excessive SleepinessClinical Trials (1)
NCT04788953Clinical Trial of Solriamfetol for Excessive Sleepiness Related to Shift Work Disorder
Phase 4Phase 4
Clinical Trials (1)
NCT06223880A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
Phase 4Solriamfetol 75 MG
InsomniaClinical Trials (1)
NCT05838430Solriamfetol and CBT-I in Patients With Insomnia Disorder
Phase 4Solriamfetol
Excessive Daytime SleepinessClinical Trials (1)
NCT04789174Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study
Phase 4Open Jobs (182)
Clinical Trial Manager/Senior Clinical Trial Manager
New York, NY
Clinical Development9h ago
$130K - $150K/yr
Specialty Account Manager, Auvelity (Hammond, IN)
Hammond, IN
Commercial20h ago
$100K - $150K/yr
Specialty Account Manager, Symbravo (Indianapolis N, IN)
Indianapolis, IN
CommercialYesterday
$100K - $150K/yr
Specialty Account Manager, Sunosi (Indianapolis N, IN)
Indianapolis, IN
CommercialYesterday
$110K - $150K/yr
Medical Science Liaison/Senior Medical Science Liaison, Migraine (Southeast)
Miami, FL
Medical AffairsYesterday
$150K - $200K/yr
Specialty Account Manager, Sunosi (South Utah)
St. George, UT
Commercial3d ago
$110K - $150K/yr
Specialty Account Manager, Auvelity (Lubbock, TX)
Lubbock, TX
Commercial3d ago
$100K - $150K/yr
Specialty Account Manager, Symbravo (Charleston, SC)
Charleston, SC
Commercial5d ago
$100K - $150K/yr
Associate/Senior Associate, Pricing and Contracting
New York, NY
Commercial6d ago
$70K - $85K/yr
Specialty Account Manager, Symbravo (Fayetteville, NC)
Fayetteville, NC
Commercial1w ago
$100K - $150K/yr
Medical Science Liaison/Senior Medical Science Liaison, Alzheimer's Disease Agitation (Midwest Region)
Cincinnati, Ohio
Medical Affairs1w ago
$150K - $200K/yr
Specialty Account Manager, Symbravo SAM (Kansas City E, MO)
Kansas City, MO
Commercial1w ago
$100K - $150K/yr
Specialty Account Manager, Symbravo (Edison, NJ)
Edison, NJ
Commercial1w ago
$100K - $150K/yr
Senior Manager, Field Effectiveness
New York, NY
Commercial1w ago
$140K - $160K/yr
Regional Business Director, Auvelity (Northern NJ)
Edison, NJ
Commercial1w ago
$165K - $205K/yr
Manager, Clinical Data Management
New York, NY
Clinical Development1w ago
$125K - $140K/yr
Associate/Senior Associate, Market Access Data Science
New York, NY
Commercial1w ago
$70K - $90K/yr
Medical Science Liaison/Senior Medical Science Liaison, Alzheimer's Disease Agitation (Mountain Region)
Phoenix, AZ
Medical Affairs2w ago
$150K - $200K/yr
Health Outcomes Liaison/Sr. Health Outcomes Liaison
New York, NY
Medical Affairs2w ago
$155K - $205K/yr
Specialty Account Manager, Auvelity (Las Vegas, NV)
Las Vegas, NV
Commercial2w ago
$100K - $150K/yr
Associate Director/Director, Regulatory Affairs
New York, NY
Regulatory Affairs2w ago
$160K - $215K/yr
Senior Manager, Digital Analytics
New York, NY
Commercial2w ago
$140K - $160K/yr
Specialty Account Manager, Auvelity (Kansas City, MO)
Kansas City, MO
Commercial2w ago
$100K - $150K/yr
Specialty Account Manager, Symbravo (Cleveland, OH)
Cleveland, OH
Commercial2w ago
$100K - $150K/yr
Manager, Accounts Payable
New York, NY
Finance2w ago
$85K - $110K/yr
Interview Prep Quick Facts
Portfolio: 3 approved products, 35 clinical trials
Top TAs: Neurology, Musculoskeletal, Psychiatry
Open Roles: 182 active jobs
Portfolio Health
Growth1 (33%)
Peak2 (67%)
3 total products
Therapeutic Area Focus
Marketed
Pipeline
Hiring Trend
Slowing Down
182
Open Roles
+13
Added
-65
Filled/Removed
Based on last 4 crawl cycles